Other Information
−Removed: On May 30, 2023 , Chief Executive Officer Gary Owens entered into a written plan for the purchase or sale of securities of the registrant intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5 - 1 (c) (“Rule 10b5 - 1 trading arrangement”).
−Removed: The trading plan is effective through April 26, 2024 .
−Removed: The trading plan contemplates that Mr.
−Removed: Owens may sell up to 11,950  shares of Mesa Labs' common stock, subject to certain trading conditions. 
+Added: The following of our directors or officers entered into written plans for the purchase or sale of our securities intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5 - 1 (c) (each, a "trading arrangement") on the dates indicated:
+Added: Director John Schmieder entered into a trading arrangement on June 14, 2023 .
+Added: The trading arrangement was effective through September 15, 2023 .
+Added: The trading arrangement contemplated that Mr.
+Added: Schmieder could sell up to 7,000 shares of Mesa Labs' common stock, subject to certain conditions. 
+Added: Chief Financial Officer John Sakys entered into a trading arrangement on August 23, 2023 .
+Added: The trading arrangement is effective through April 2, 2024.
+Added: The trading arrangement contemplates that Mr.
+Added: Sakys may exercise up to 2,500 non-qualified stock options and sell the resulting 2,500 shares of Mesa Labs' common stock, subject to certain conditions.
+Added: Senior Vice President of Continuous Improvement Brian Archbold entered into a trading arrangement on September 14, 2023 .
+Added: The trading arrangement is effective through April 2, 2024 .
+Added: The trading arrangement contemplates that Mr.
+Added: Archbold may exercise 710 non-qualified stock options and sell the resulting 710 shares of Mesa Labs' common stock, subject to certain conditions.
+Added: The trading arrangement further contemplates that Mr.
+Added: Archbold may sell an additional 1,500 shares of Mesa Labs' common stock, subject to certain conditions.
Description of Exhibit
−Removed: Articles of Incorporation and Amendments to Articles of Incorporation (incorporated by reference from exhibit 3.1 to Mesa Laboratories, Inc.
−Removed: s report on Form 10-Q filed on July 31, 2018 (Commission File Number:
+Added: Amended and Restated Articles of Incorporation of Mesa Laboratories, Inc.
+Added: (incorporated by reference from exhibit 3.1 to the Current Report on Form 8-K filed August 25, 2023 (Commission File Number:
Amended and Restated Bylaws of Mesa Laboratories, Inc.
(incorporated by reference from exhibit 3.1 to the Current Report on Form 8-K filed on May 10, 2019 (Commission File Number:
+Added: Amendment No.
+Added: 2 to Credit Agreement dated as of October 5, 2023 among the Company, the lenders party thereto, and JPMorgan Chase Bank, NA., as administrative agent.
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
13 unchanged sentences
MESA LABORATORIES, INC.
−Removed: DATED: August 3, 2023
+Added: DATED: November 6, 2023
Chief Executive Officer
−Removed: DATED: August 3, 2023
+Added: DATED: November 6, 2023
Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.